Author

Amber Stiby

University of Birmingham

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Abeer M. ShaabaniD· 1 shared Anna Munsey· 1 shared Bohdana-Myroslava Briantseva· 1 shared Ciara M. Ward· 1 shared Clare C. DaviesiD· 1 shared Graeme C.M. SmithiD· 1 shared Kirendeep Jawanda· 1 shared Marco SaponaroiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Abeer M. ShaabanORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

MYBL2 maintains stemness and promotes theta-mediated end joining in triple negative breast cancer

Rachel Bayley, Anna Munsey, Suman Ahmed, Ciara M. Ward, Amber Stiby, Bohdana-Myroslava Briantseva, Kirendeep Jawanda, Abeer M. Shaaban, Marco Saponaro, Graeme C.M. Smith, Robert B. Clarke, Clare C. Davies, Paloma García

This study shows MYBL2 maintains stemness and promotes theta-mediated end joining in TNBC, and identifies Pol{theta}/ATR inhibition as a therapeutic strategy.

bioRxiv · Apr 15, 2025 · PreprintCancer Biology